Literature DB >> 1600691

Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation.

N Win1, D Mitchell, S Pugh, N H Russell.   

Abstract

A 21-year-old patient developed interstitial pneumonitis nine months post bone marrow transplant for acute myeloblastic leukaemia. Immunofluorescence of broncheoalveolar lavage fluid revealed the presence of respiratory syncytial virus (RSV). Aerosolized ribavarin therapy resulted in rapid resolution of the pneumonitis with full recovery without any side effects. Ribavarin therapy should be considered early in the management of BMT patients who develop RSV pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600691

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  8 in total

1.  Respiratory syncytial virus pneumonia in an AIDS patient.

Authors:  A J van der Ven; C M Swanink; R van Crevel; G P Bootsma; P P Koopmans; J M Galama
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

Review 2.  Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

Authors:  M G Ottolini; V G Hemming
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

3.  Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Authors:  Lia M Haynes; Joelyn Tonkin; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 4.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 5.  Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors:  Fareed Khawaja; Roy F Chemaly
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

Review 6.  Respiratory viral infections in immunocompetent and immunocompromised persons.

Authors:  R B Couch; J A Englund; E Whimbey
Journal:  Am J Med       Date:  1997-03-17       Impact factor: 4.965

Review 7.  Community respiratory virus infections in immunocompromised patients with cancer.

Authors:  E Whimbey; J A Englund; R B Couch
Journal:  Am J Med       Date:  1997-03-17       Impact factor: 4.965

8.  Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.

Authors:  Hayat Caidi; Jennifer L Harcourt; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.